177 related articles for article (PubMed ID: 37441081)
1. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Basso J; Chen KJ; Zhou Y; Mark L; LaSala D; Dorfman A; Atalla M; Chun D; Viramontes V; Chang C; Leifer F; McDonald PP; Cipolla DC
Front Pharmacol; 2023; 14():1208780. PubMed ID: 37538173
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
4. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
McDonald PP; Leifer FG; Basso J; Lasala D; Li D; Chen KJ; Zhang J; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1231047. PubMed ID: 37638021
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
[TBL] [Abstract][Full Text] [Related]
6. HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage.
Knapp J; Braunstein M; Berg SIT; Shirriff C
Arthritis Res Ther; 2022 Dec; 24(1):267. PubMed ID: 36510250
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
Usansky H; Yoon E; Teper A; Zou J; Fernandez C
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):832-842. PubMed ID: 35411669
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.
Gardiner P; Wikell C; Clifton S; Shearer J; Benjamin A; Peters SA
Br J Pharmacol; 2016 Aug; 173(15):2390-401. PubMed ID: 27186823
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor.
Kawato Y; Fukahori H; Nakamura K; Kubo K; Hiramitsu M; Kinugasa F; Morokata T
Eur J Pharmacol; 2023 Jan; 938():175440. PubMed ID: 36463947
[TBL] [Abstract][Full Text] [Related]
11. Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.
Gardet A; Chou WC; Reynolds TL; Velez DB; Fu K; Czerkowicz JM; Bajko J; Ranger AM; Allaire N; Kerns HM; Ryan S; Legault HM; Dunstan RW; Lafyatis R; Lukashev M; Viney JL; Browning JL; Rabah D
PLoS One; 2016; 11(10):e0164423. PubMed ID: 27760209
[TBL] [Abstract][Full Text] [Related]
12. Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.
Seo Y; Mun CH; Park SH; Jeon D; Kim SJ; Yoon T; Ko E; Jo S; Park YB; Namkung W; Lee SW
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32674502
[TBL] [Abstract][Full Text] [Related]
13. Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage.
He S; Liu X; Lin Z; Liu Y; Gu L; Zhou H; Tang W; Zuo J
Arthritis Res Ther; 2019 Jan; 21(1):40. PubMed ID: 30696480
[TBL] [Abstract][Full Text] [Related]
14. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular changes in the NZB/W F1 mouse model of lupus nephritis.
Böhme R; Daniel C; Ferrazzi F; Angeloni M; Ekici AB; Winkler TH; Hilgers KF; Wellmann U; Voll RE; Amann K
Front Cardiovasc Med; 2023; 10():1182193. PubMed ID: 37554366
[TBL] [Abstract][Full Text] [Related]
16. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
Chen K; Deng Y; Shang S; Tang L; Li Q; Bai X; Chen X
Biomed Pharmacother; 2022 Sep; 153():113433. PubMed ID: 36076550
[TBL] [Abstract][Full Text] [Related]
17. Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis.
Gunsolley JC; Chalmers JD; Sibila O; Fernandez C; Scannapieco FA
JDR Clin Trans Res; 2023 Sep; ():23800844231196884. PubMed ID: 37746735
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Pohlmeyer CW; Shang C; Han P; Cui ZH; Jones RM; Clarke AS; Murray BP; Lopez DA; Newstrom DW; Inzunza MD; Matzkies FG; Currie KS; Di Paolo JA
BMC Rheumatol; 2021 Mar; 5(1):15. PubMed ID: 33781343
[TBL] [Abstract][Full Text] [Related]
19. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
Wu L; Jiang X; Qi C; Zhang C; Qu B; Shen N
Front Immunol; 2021; 12():653989. PubMed ID: 33868295
[TBL] [Abstract][Full Text] [Related]
20. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
